{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:23:45Z","timestamp":1793201025771,"version":"4.5.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-024-03763-8","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:07:46Z","timestamp":1734527266000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["The double life of glucose metabolism: brain health, glycemic homeostasis, and your patients with type 2 diabetes"],"prefix":"10.1186","volume":"22","author":[{"given":"Stanley S.","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Thet Hmu","family":"Tun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Allan","family":"Butterfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"Supplement_1","key":"3763_CR1","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc23-S013","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Older adults: standards of care in diabetes\u20142023. Diabetes Care. 2023;46(Supplement_1):S216\u201329.","journal-title":"Diabetes Care."},{"key":"3763_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/186106","volume":"2013","author":"K Alagiakrishnan","year":"2013","unstructured":"Alagiakrishnan K, Zhao N, Mereu L, Senior P, Senthilselvan A. Montreal cognitive assessment is superior to standardized mini-mental status exam in detecting mild cognitive impairment in the middle-aged and elderly patients with type 2 diabetes mellitus. Biomed Res Int. 2013;2013:1\u20135.","journal-title":"Biomed Res Int"},{"issue":"7","key":"3763_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1515\/revneuro-2017-0016","volume":"28","author":"X-Y Yuan","year":"2017","unstructured":"Yuan X-Y, Wang X-G. Mild cognitive impairment in type 2 diabetes mellitus and related risk factors: a review. Rev Neurosci. 2017;28(7):715\u201323.","journal-title":"Rev Neurosci"},{"key":"3763_CR4","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2022 [Accessed 2023 Oct 25]. Available from: https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report"},{"key":"3763_CR5","unstructured":"U.S. Centers for Disease Control and Prevention. No Title. National Diabetes Statistics Report. 2024 [Accessed 2024 Jun 25]."},{"issue":"2","key":"3763_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jalz.2017.10.009","volume":"14","author":"R Brookmeyer","year":"2018","unstructured":"Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer\u2019s disease in the United States. Alzheimer\u2019s Dement. 2018;14(2):121\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"3763_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1515\/biol-2019-0029","volume":"14","author":"H Zhao","year":"2019","unstructured":"Zhao H, Wu C, Zhang X, Wang L, Sun J, Zhuge F. Insulin resistance is a risk factor for mild cognitive impairment in elderly adults with T2DM. Open Life Sci. 2019;14(1):255\u201361.","journal-title":"Open Life Sci"},{"issue":"12","key":"3763_CR8","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.jalz.2018.08.004","volume":"14","author":"RS Isaacson","year":"2018","unstructured":"Isaacson RS, Ganzer CA, Hristov H, Hackett K, Caesar E, Cohen R, et al. The clinical practice of risk reduction for Alzheimer\u2019s disease: a precision medicine approach. Alzheimer\u2019s Dement. 2018;14(12):1663\u201373.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"17","key":"3763_CR9","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. Circulation. 2005;112(17):2735\u201352.","journal-title":"Circulation"},{"issue":"1","key":"3763_CR10","doi-asserted-by":"publisher","first-page":"16128","DOI":"10.1038\/s41598-018-33843-8","volume":"8","author":"N Mallorqu\u00ed-Bagu\u00e9","year":"2018","unstructured":"Mallorqu\u00ed-Bagu\u00e9 N, Lozano-Madrid M, Toledo E, Corella D, Salas-Salvad\u00f3 J, Cuenca-Royo A, et al. Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study. Sci Rep. 2018;8(1):16128.","journal-title":"Sci Rep"},{"issue":"5","key":"3763_CR11","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41591-024-02931-w","volume":"30","author":"J Fortea","year":"2024","unstructured":"Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaqu\u00e9-Alc\u00e1zar L, et al. APOE4 homozygosity represents a distinct genetic form of Alzheimer\u2019s disease. Nat Med. 2024;30(5):1284\u201391.","journal-title":"Nat Med"},{"key":"3763_CR12","doi-asserted-by":"crossref","unstructured":"Jaarsma E, Nooyens A, Kok AAL, K\u00f6hler S, van Boxtel M, Verschuren WMM, et al. Modifiable risk factors for accelerated decline in processing speed: results from three Dutch population cohorts. J Prev Alzheimer\u2019s Dis. 2024;11(1):108\u201316.","DOI":"10.14283\/jpad.2023.64"},{"issue":"1","key":"3763_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/metabo13010087","volume":"13","author":"S Stanciu","year":"2023","unstructured":"Stanciu S, Rusu E, Miricescu D, Radu AC, Axinia B, Vrabie AM, et al. Links between metabolic syndrome and hypertension: the relationship with the current antidiabetic drugs. Metabolites. 2023;13(1):87.","journal-title":"Metabolites"},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/179648","volume":"2014","author":"M Gorska-Ciebiada","year":"2014","unstructured":"Gorska-Ciebiada M, Saryusz-Wolska M, Ciebiada M, Loba J. Mild cognitive impairment and depressive symptoms in elderly patients with diabetes: prevalence, risk factors, and comorbidity. J Diabetes Res. 2014;2014:1\u20137.","journal-title":"J Diabetes Res"},{"issue":"3","key":"3763_CR15","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.13601","volume":"20","author":"Y Lu","year":"2024","unstructured":"Lu Y, Pike JR, Hoogeveen RC, Walker KA, Raffield LM, Selvin E, et al. Liver integrity and the risk of Alzheimer\u2019s disease and related dementias. Alzheimers Dement. 2024;20(3):1913\u201322.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"3763_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus \u2014 mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599\u2013612.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"3763_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2337\/dc13-1384","volume":"37","author":"I Feinkohl","year":"2014","unstructured":"Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, McLachlan S, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014;37(2):507\u201315.","journal-title":"Diabetes Care"},{"issue":"14","key":"3763_CR18","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1001\/jamainternmed.2013.6176","volume":"173","author":"K Yaffe","year":"2013","unstructured":"Yaffe K. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173(14):1300.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"3763_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S2213-8587(13)70088-3","volume":"2","author":"GJ Biessels","year":"2014","unstructured":"Biessels GJ, Strachan MWJ, Visseren FLJ, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol. 2014;2(3):246\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3763_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2337\/dc15-1588","volume":"39","author":"S Chatterjee","year":"2016","unstructured":"Chatterjee S, Peters SAE, Woodward M, Mejia Arango S, Batty GD, Beckett N, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39(2):300\u20137.","journal-title":"Diabetes Care."},{"key":"3763_CR21","doi-asserted-by":"publisher","first-page":"100944","DOI":"10.1016\/j.arr.2019.100944","volume":"55","author":"M Xue","year":"2019","unstructured":"Xue M, Xu W, Ou Y-N, Cao X-P, Tan M-S, Tan L, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev. 2019;55:100944.","journal-title":"Ageing Res Rev"},{"key":"3763_CR22","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1017\/S2045796020000347","volume":"29","author":"JQ Thomassen","year":"2020","unstructured":"Thomassen JQ, Tolstrup JS, Benn M, Frikke-Schmidt R. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals. Epidemiol Psychiatr Sci. 2020;29:e118.","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"6","key":"3763_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S2213-8587(20)30118-2","volume":"8","author":"V Srikanth","year":"2020","unstructured":"Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ. Type 2 diabetes and cognitive dysfunction\u2014towards effective management of both comorbidities. Lancet Diabetes Endocrinol. 2020;8(6):535\u201345.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"3763_CR24","doi-asserted-by":"publisher","first-page":"e001741","DOI":"10.1136\/bmjdrc-2020-001741","volume":"8","author":"C Willmann","year":"2020","unstructured":"Willmann C, Brockmann K, Wagner R, Kullmann S, Preissl H, Schnauder G, et al. Insulin sensitivity predicts cognitive decline in individuals with prediabetes. BMJ Open Diabetes Res Care. 2020;8(2):e001741.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"9","key":"3763_CR25","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.bbadis.2014.06.010","volume":"1842","author":"DA Butterfield","year":"2014","unstructured":"Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta - Mol Basis Dis. 2014;1842(9):1693\u2013706.","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"4","key":"3763_CR26","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1007\/s12035-018-1231-5","volume":"56","author":"E Barone","year":"2019","unstructured":"Barone E, Tramutola A, Triani F, Calcagnini S, Di Domenico F, Ripoli C, et al. Biliverdin reductase-a mediates the beneficial effects of intranasal insulin in alzheimer disease. Mol Neurobiol. 2019;56(4):2922\u201343.","journal-title":"Mol Neurobiol"},{"issue":"s2","key":"3763_CR27","doi-asserted-by":"publisher","first-page":"S535","DOI":"10.3233\/JAD-2010-100342","volume":"20","author":"N Dragicevic","year":"2010","unstructured":"Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, et al. Mitochondrial amyloid-\u03b2 levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer\u2019s transgenic mice. Zhu X, Beal MF, Wang X, Perry G, Smith MA, editors. J Alzheimer\u2019s Dis. 2010;20(s2):S535\u201350.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"3763_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnins.2015.00204","volume":"9","author":"G Bedse","year":"2015","unstructured":"Bedse G, Di Domenico F, Serviddio G, Cassano T. Aberrant insulin signaling in Alzheimer\u2019s disease: current knowledge. Front Neurosci. 2015;9:204.","journal-title":"Front Neurosci"},{"issue":"8","key":"3763_CR29","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.2337\/dc09-2030","volume":"33","author":"AM Abbatecola","year":"2010","unstructured":"Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care. 2010;33(8):1706\u201311.","journal-title":"Diabetes Care"},{"issue":"1","key":"3763_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/nyas.12807","volume":"1353","author":"A Moheet","year":"2015","unstructured":"Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015;1353(1):60\u201371.","journal-title":"Ann N Y Acad Sci"},{"issue":"859","key":"3763_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.freeradbiomed.2021.09.006","volume":"176","author":"E Barone","year":"2021","unstructured":"Barone E, Di Domenico F, Perluigi M, Butterfield DA. The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radic Biol Med. 2021;176(859):16\u201333.","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"3763_CR32","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.bbadis.2011.01.005","volume":"1812","author":"E Barone","year":"2011","unstructured":"Barone E, Di Domenico F, Cenini G, Sultana R, Cini C, Preziosi P, et al. Biliverdin reductase-A protein levels and activity in the brains of subjects with Alzheimer disease and mild cognitive impairment. Biochim Biophys Acta - Mol Basis Dis. 2011;1812(4):480\u20137.","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"3","key":"3763_CR33","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3233\/JAD-170829","volume":"62","author":"SM de la Monte","year":"2018","unstructured":"de la Monte SM, Tong M, Wands JR. The 20-year voyage aboard the journal of Alzheimer\u2019s disease: docking at \u2018type 3 diabetes\u2019, environmental\/exposure factors, pathogenic mechanisms, and potential treatments. Perry G, Avila J, Tabaton M, Zhu X, editors. J Alzheimer\u2019s Dis. 2018;62(3):1381\u201390.","journal-title":"J Alzheimer\u2019s Dis."},{"issue":"11","key":"3763_CR34","first-page":"e19176","volume":"13","author":"A Alkasabera","year":"2021","unstructured":"Alkasabera A, Onyali CB, Anim-Koranteng C, Shah HE, Ethirajulu A, Bhawnani N, et al. The effect of type-2 diabetes on cognitive status and the role of anti-diabetes medications. Cureus. 2021;13(11):e19176.","journal-title":"Cureus"},{"key":"3763_CR35","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.3390\/ijms24043506","volume":"24","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Hwang JH, Son SU, Choi J, You SW, Park H, et al. How can insulin resistance cause Alzheimer\u2019s disease? Int J Mol Sci MDPI. 2023;24:3506.","journal-title":"Int J Mol Sci. MDPI"},{"issue":"7","key":"3763_CR36","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/jcbfm.2012.35","volume":"32","author":"C Howarth","year":"2012","unstructured":"Howarth C, Gleeson P, Attwell D. Updated energy budgets for neural computation in the neocortex and cerebellum. J Cereb Blood Flow Metab. 2012;32(7):1222\u201332.","journal-title":"J Cereb Blood Flow Metab"},{"key":"3763_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20:148\u201360.","journal-title":"Nat Rev Neurosci."},{"issue":"1","key":"3763_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1152\/physrev.00030.2022","volume":"104","author":"M Perluigi","year":"2024","unstructured":"Perluigi M, Di Domenico F, Butterfield DA. Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease. Physiol Rev. 2024;104(1):103\u201397.","journal-title":"Physiol Rev"},{"issue":"11","key":"3763_CR39","doi-asserted-by":"publisher","first-page":"7653","DOI":"10.1002\/jcp.29682","volume":"235","author":"BL Tang","year":"2020","unstructured":"Tang BL. Glucose, glycolysis, and neurodegenerative diseases. J Cell Physiol. 2020;235(11):7653\u201362.","journal-title":"J Cell Physiol"},{"issue":"8","key":"3763_CR40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.metabol.2005.02.018","volume":"54","author":"RE Seaquist","year":"2005","unstructured":"Seaquist RE, Tkac I, Damberg G, Thomas W, Gruetter R. Brain glucose concentrations in poorly controlled diabetes mellitus as measured by high-field magnetic resonance spectroscopy. Metabolism. 2005;54(8):1008\u201313.","journal-title":"Metabolism"},{"issue":"12","key":"3763_CR41","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1053\/meta.2002.36347","volume":"51","author":"RJ Jacob","year":"2002","unstructured":"Jacob RJ, Fan X, Evans ML, Dziura J, Sherwin RS. Brain glucose levels are elevated in chronically hyperglycemic diabetic rats: No evidence for protective adaptation by the blood brain barrier. Metabolism. 2002;51(12):1522\u20134.","journal-title":"Metabolism"},{"issue":"4","key":"3763_CR42","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s00125-014-3169-0","volume":"57","author":"GP Holloway","year":"2014","unstructured":"Holloway GP, Han XX, Jain SS, Bonen A, Chabowski A. Chronic muscle stimulation improves insulin sensitivity while increasing subcellular lipid droplets and reducing selected diacylglycerol and ceramide species in obese Zucker rats. Diabetologia. 2014;57(4):832\u201340.","journal-title":"Diabetologia"},{"issue":"10","key":"3763_CR43","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/nu10101530","volume":"10","author":"M Maciejczyk","year":"2018","unstructured":"Maciejczyk M, Matczuk J, \u017bendzian-Piotrowska M, Nikli\u0144ska W, Fejfer K, Szarmach I, et al. Eight-week consumption of high-sucrose diet has a pro-oxidant effect and alters the function of the salivary glands of rats. Nutrients. 2018;10(10):1530.","journal-title":"Nutrients"},{"key":"3763_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","volume":"14","author":"SE Arnold","year":"2018","unstructured":"Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, et al. Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nat Rev Neurol. 2018;14:168\u201381.","journal-title":"Nat Rev Neurol."},{"issue":"4","key":"3763_CR45","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer\u2019s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316\u201338.","journal-title":"J Clin Invest"},{"issue":"22","key":"3763_CR46","doi-asserted-by":"publisher","first-page":"12366","DOI":"10.3390\/ijms222212366","volume":"22","author":"FC Pignalosa","year":"2021","unstructured":"Pignalosa FC, Desiderio A, Mirra P, Nigro C, Perruolo G, Ulianich L, et al. Diabetes and cognitive impairment: a role for glucotoxicity and dopaminergic dysfunction. Int J Mol Sci. 2021;22(22):12366.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3763_CR47","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2337\/dbi19-0014","volume":"69","author":"M Prentki","year":"2020","unstructured":"Prentki M, Peyot M-L, Masiello P, Madiraju SRM. Nutrient-induced metabolic stress, adaptation, detoxification, and toxicity in the pancreatic \u03b2-cell. Diabetes. 2020;69(3):279\u201390.","journal-title":"Diabetes"},{"key":"3763_CR48","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2147\/IJGM.S305156","volume":"14","author":"AW Rachfal","year":"2021","unstructured":"Rachfal AW, Grant SF, Schwartz SS. The diabetes syndrome \u2013 a collection of conditions with common, interrelated pathophysiologic mechanisms. Int J Gen Med. 2021;14:923\u201336.","journal-title":"Int J Gen Med"},{"issue":"13","key":"3763_CR49","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.2174\/1381612826666200325110014","volume":"26","author":"WA Banks","year":"2020","unstructured":"Banks WA. The blood-brain barrier interface in diabetes mellitus: dysfunctions, mechanisms and approaches to treatment. Curr Pharm Des. 2020;26(13):1438\u201347.","journal-title":"Curr Pharm Des"},{"key":"3763_CR50","first-page":"1","volume":"2014","author":"L-J Yan","year":"2014","unstructured":"Yan L-J. Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. J Diabetes Res. 2014;2014:1\u201311.","journal-title":"J Diabetes Res"},{"key":"3763_CR51","doi-asserted-by":"crossref","unstructured":"Ruegsegger GN, Vanderboom PM, Dasari S, Klaus KA, Kabiraj P, McCarthy CB, et al. Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain. JCI Insight. 2019;4(18):e130681.","DOI":"10.1172\/jci.insight.130681"},{"key":"3763_CR52","doi-asserted-by":"crossref","unstructured":"De Felice FG, Lourenco MV, Ferreira ST. How does brain insulin resistance develop in Alzheimer\u2019s disease? Alzheimer\u2019s Dement. 2014;10(1 Suppl):S26\u201332.","DOI":"10.1016\/j.jalz.2013.12.004"},{"issue":"10","key":"3763_CR53","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.bbadis.2016.07.005","volume":"1862","author":"M Perluigi","year":"2016","unstructured":"Perluigi M, Barone E, Di Domenico F, Butterfield DA. Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways. Biochim Biophys Acta - Mol Basis Dis. 2016;1862(10):1871\u201382.","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"23","key":"3763_CR54","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.3390\/cells11233767","volume":"11","author":"DD Singh","year":"2022","unstructured":"Singh DD, Shati AA, Alfaifi MY, Elbehairi SEI, Han I, Choi E-H, et al. Development of dementia in type 2 diabetes patients: mechanisms of insulin resistance and antidiabetic drug development. Cells. 2022;11(23):3767.","journal-title":"Cells"},{"issue":"1","key":"3763_CR55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40478-021-01176-9","volume":"9","author":"Z Arvanitakis","year":"2021","unstructured":"Arvanitakis Z, Capuano AW, Wang H-Y, Schneider JA, Kapasi A, Bennett DA, et al. Brain insulin signaling and cerebrovascular disease in human postmortem brain. Acta Neuropathol Commun. 2021;9(1):71.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"3763_CR56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13205-021-02738-3","volume":"11","author":"M Zheng","year":"2021","unstructured":"Zheng M, Wang P. Role of insulin receptor substance-1 modulating PI3K\/Akt insulin signaling pathway in Alzheimer\u2019s disease. 3 Biotech. 2021;11(4):179.","journal-title":"3 Biotech."},{"issue":"5","key":"3763_CR57","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/jnc.13037","volume":"133","author":"A Tramutola","year":"2015","unstructured":"Tramutola A, Triplett JC, Di Domenico F, Niedowicz DM, Murphy MP, Coccia R, et al. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J Neurochem. 2015;133(5):739\u201349.","journal-title":"J Neurochem"},{"issue":"4","key":"3763_CR58","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/jnc.14589","volume":"151","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Boyd-Kimball D. Redox proteomics and amyloid \u03b2-peptide: insights into Alzheimer disease. J Neurochem. 2019;151(4):459\u201387.","journal-title":"J Neurochem"},{"key":"3763_CR59","doi-asserted-by":"crossref","unstructured":"Lu Y, Jiang X, Liu S, Li M. Changes in cerebrospinal fluid tau and \u03b2-amyloid levels in diabetic and prediabetic patients: a meta-analysis. Front Aging Neurosci. 2018:10:271.","DOI":"10.3389\/fnagi.2018.00271"},{"issue":"3","key":"3763_CR60","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3233\/JAD-130584","volume":"37","author":"H Xiong","year":"2013","unstructured":"Xiong H, Zheng C, Wang J, Song J, Zhao G, Shen H, et al. The neuroprotection of liraglutide on Alzheimer-like learning and memory impairment by modulating the hyperphosphorylation of tau and neurofilament proteins and insulin signaling pathways in mice. Alonso A, Gong C, editors. J Alzheimer\u2019s Dis. 2013;37(3):623\u201335.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"3763_CR61","doi-asserted-by":"crossref","unstructured":"Cho SB. Comorbidity genes of Alzheimer\u2019s disease and type 2 diabetes associated with memory and cognitive function. Int J Mol Sci. 2024;25(4):2211.","DOI":"10.3390\/ijms25042211"},{"key":"3763_CR62","doi-asserted-by":"publisher","first-page":"106485","DOI":"10.1016\/j.nbd.2024.106485","volume":"196","author":"E Lemche","year":"2024","unstructured":"Lemche E, Killick R, Mitchell J, Caton PW, Choudhary P, Howard JK. Molecular mechanisms linking type 2 diabetes mellitus and late-onset Alzheimer\u2019s disease: a systematic review and qualitative meta-analysis. Neurobiol Dis. 2024;196:106485.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"3763_CR63","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13148-023-01589-4","volume":"15","author":"C Sarnowski","year":"2023","unstructured":"Sarnowski C, Huan T, Ma Y, Joehanes R, Beiser A, DeCarli CS, et al. Multi-tissue epigenetic analysis identifies distinct associations underlying insulin resistance and Alzheimer\u2019s disease at CPT1A locus. Clin Epigenetics. 2023;15(1):173.","journal-title":"Clin Epigenetics"},{"issue":"9","key":"3763_CR64","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.tem.2017.05.005","volume":"28","author":"SS Schwartz","year":"2017","unstructured":"Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR III, Aguilar RB, et al. A unified pathophysiological construct of diabetes and its complications. Trends Endocrinol Metab. 2017;28(9):645\u201355.","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"3763_CR65","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1046\/j.1532-5415.2003.51465.x","volume":"51","author":"S Borson","year":"2003","unstructured":"Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a Screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51(10):1451\u20134.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"3763_CR66","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"3763_CR67","doi-asserted-by":"publisher","first-page":"687.e5","DOI":"10.1016\/j.jamda.2014.05.004","volume":"15","author":"DM Cruz-Oliver","year":"2014","unstructured":"Cruz-Oliver DM, Malmstrom TK, Roegner M, Tumosa N, Grossberg GT. Cognitive deficit reversal as shown by changes in the Veterans Affairs Saint Louis University Mental Status (SLUMS) examination scores 7.5 years later. J Am Med Dir Assoc. 2014;15(9):687.e5\u2013687.e10.","journal-title":"J Am Med Dir Assoc."},{"issue":"3","key":"3763_CR68","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3233\/JAD-201403","volume":"82","author":"E Tsoy","year":"2021","unstructured":"Tsoy E, Sideman AB, Pi\u00f1a Escudero SD, Pintado-Caipa M, Kanjanapong S, Al-Rousan T, et al. Global perspectives on brief cognitive assessments for dementia diagnosis. J Alzheimer\u2019s Dis. 2021;82(3):1001\u201313.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"3","key":"3763_CR69","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1212\/CON.0000000000001135","volume":"28","author":"S Weintraub","year":"2022","unstructured":"Weintraub S. Neuropsychological assessment in dementia diagnosis. Contin Lifelong Learn Neurol. 2022;28(3):781\u201399.","journal-title":"Contin Lifelong Learn Neurol"},{"issue":"14","key":"3763_CR70","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, Schmitt F, Ferris S, M\u00f6bius HJ. Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2003;348(14):1333\u201341.","journal-title":"N Engl J Med"},{"issue":"3","key":"3763_CR71","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3233\/JAD-220361","volume":"88","author":"AS Bukhbinder","year":"2022","unstructured":"Bukhbinder AS, Ling Y, Hasan O, Jiang X, Kim Y, Phelps KN, et al. Risk of Alzheimer\u2019s disease following influenza vaccination: a claims-based cohort study using propensity score matching. Kostev K, editor. J Alzheimer\u2019s Dis. 2022;88(3):1061\u201374.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"3763_CR72","doi-asserted-by":"crossref","unstructured":"Schnier C, Janbek J, Lathe R, Haas J. Reduced dementia incidence after varicella zoster vaccination in Wales 2013\u20132020. Alzheimer\u2019s Dement Transl Res Clin Interv. 2022;8(1):e12293.","DOI":"10.1002\/trc2.12293"},{"key":"3763_CR73","doi-asserted-by":"crossref","unstructured":"Mullard A. FDA approves third anti-amyloid antibody for Alzheimer disease. Nat Rev Drug Discov. 2024;23(8):571.","DOI":"10.1038\/d41573-024-00116-1"},{"issue":"5","key":"3763_CR74","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-19-0259","volume":"181","author":"IK Wium-Andersen","year":"2019","unstructured":"Wium-Andersen IK, Osler M, J\u00f8rgensen MB, Rungby J, Wium-Andersen MK. Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study. Eur J Endocrinol. 2019;181(5):499\u2013507.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"3763_CR75","doi-asserted-by":"publisher","first-page":"e3673","DOI":"10.1002\/dmrr.3673","volume":"39","author":"S Tian","year":"2023","unstructured":"Tian S, Jiang J, Wang J, Zhang Z, Miao Y, Ji X, et al. Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis. Diabetes Metab Res Rev. 2023;39(7):e3673.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"3763_CR76","doi-asserted-by":"publisher","first-page":"37","DOI":"10.14336\/AD.2017.1202","volume":"10","author":"T Chin-Hsiao","year":"2019","unstructured":"Chin-Hsiao T. Metformin and the risk of dementia in type 2 diabetes patients. Aging Dis. 2019;10(1):37.","journal-title":"Aging Dis"},{"issue":"2","key":"3763_CR77","doi-asserted-by":"publisher","first-page":"e0212293","DOI":"10.1371\/journal.pone.0212293","volume":"14","author":"G Weinstein","year":"2019","unstructured":"Weinstein G, Davis-Plourde KL, Conner S, Himali JJ, Beiser AS, Lee A, et al. Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer\u2019s disease: pooled analysis from 5 cohorts. Bayer A, editor. PLoS One. 2019;14(2):e0212293.","journal-title":"PLoS One."},{"issue":"6","key":"3763_CR78","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00125-021-05393-8","volume":"64","author":"GJ Biessels","year":"2021","unstructured":"Biessels GJ, Verhagen C, Janssen J, van den Berg E, Wallenstein G, Zinman B, et al. Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. Diabetologia. 2021;64(6):1235\u201345.","journal-title":"Diabetologia"},{"issue":"7","key":"3763_CR79","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S1474-4422(20)30173-3","volume":"19","author":"T Cukierman-Yaffe","year":"2020","unstructured":"Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, Garc\u00eda-P\u00e9rez L-E, Lakshmanan M, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020;19(7):582\u201390.","journal-title":"Lancet Neurol"},{"key":"3763_CR80","doi-asserted-by":"publisher","first-page":"e079475","DOI":"10.1136\/bmj-2024-079475","volume":"28","author":"A Shin","year":"2024","unstructured":"Shin A, Koo BK, Lee JY, Kang EH. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40\u201369 years with type 2 diabetes: population based cohort study. BMJ. 2024;28:e079475.","journal-title":"BMJ"},{"issue":"9","key":"3763_CR81","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3390\/medicina57090943","volume":"57","author":"D \u0160imonien\u0117","year":"2021","unstructured":"\u0160imonien\u0117 D, Veli\u010dkien\u0117 D. Relation between exogenous insulin and cognitive function in type 2 diabetes mellitus. Medicina (B Aires). 2021;57(9):943.","journal-title":"Medicina (B Aires)"},{"issue":"15","key":"3763_CR82","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jama.2009.460","volume":"301","author":"RA Whitmer","year":"2009","unstructured":"Whitmer RA. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565.","journal-title":"JAMA"},{"issue":"1","key":"3763_CR83","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/joim.12000","volume":"273","author":"C-H Lin","year":"2013","unstructured":"Lin C-H, Sheu WH-H. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med. 2013;273(1):102\u201310.","journal-title":"J Intern Med"},{"issue":"11","key":"3763_CR84","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1007\/s00125-009-1484-7","volume":"52","author":"BE de Galan","year":"2009","unstructured":"de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia. 2009;52(11):2328\u201336.","journal-title":"Diabetologia"},{"issue":"S2","key":"3763_CR85","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1002\/dmrr.514","volume":"20","author":"CG Fanelli","year":"2004","unstructured":"Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size of the problem. Diabetes Metab Res Rev. 2004;20(S2):S32\u201342.","journal-title":"Diabetes Metab Res Rev"},{"issue":"10","key":"3763_CR86","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1007\/s00125-019-4964-4","volume":"62","author":"M Nilsson","year":"2019","unstructured":"Nilsson M, Jensen N, Gejl M, Bergmann ML, Storgaard H, Zander M, et al. Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial. Diabetologia. 2019;62(10):1948\u201358.","journal-title":"Diabetologia"},{"issue":"7","key":"3763_CR87","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/dom.13690","volume":"21","author":"AJ Dunkley","year":"2019","unstructured":"Dunkley AJ, Fitzpatrick C, Gray LJ, Waheed G, Heller SR, Frier BM, et al. Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: a UK multisite 12-month prospective observational study. Diabetes, Obes Metab. 2019;21(7):1585\u201395.","journal-title":"Diabetes, Obes Metab"},{"issue":"12","key":"3763_CR88","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.2337\/dc15-1188","volume":"38","author":"C Gorst","year":"2015","unstructured":"Gorst C, Kwok CS, Aslam S, Buchan I, Kontopantelis E, Myint PK, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354\u201369.","journal-title":"Diabetes Care"},{"key":"3763_CR89","first-page":"1","volume":"2022","author":"J Song","year":"2022","unstructured":"Song J, Bai H, Xu H, Xing Y, Chen S. HbA1c variability and the risk of dementia in patients with diabetes: a meta-analysis. Seixas A, editor. Int J Clin Pract. 2022;2022:1\u201310.","journal-title":"Int J Clin Pract."},{"issue":"1","key":"3763_CR90","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","volume":"13","author":"B Lin","year":"2014","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13(1):148.","journal-title":"Cardiovasc Diabetol"},{"key":"3763_CR91","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","volume":"333","author":"P Sa-nguanmoo","year":"2017","unstructured":"Sa-nguanmoo P, Tanajak P, Kerdphoo S, Jaiwongkam T, Pratchayasakul W, Chattipakorn N, et al. SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats. Toxicol Appl Pharmacol. 2017;333:43\u201350.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"10","key":"3763_CR92","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"3763_CR93","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"3763_CR94","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2666-7568(23)00032-6","volume":"4","author":"RE Pratley","year":"2023","unstructured":"Pratley RE, Cannon CP, Cherney DZI, Cosentino F, McGuire DK, Essex MN, et al. Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Heal Longev. 2023;4(4):e143\u201354.","journal-title":"Lancet Heal Longev"},{"key":"3763_CR95","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022;146:1383\u2013405.","journal-title":"Circulation."},{"issue":"1","key":"3763_CR96","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/bab.1319","volume":"63","author":"S Shaikh","year":"2016","unstructured":"Shaikh S, Rizvi SMD, Shakil S, Riyaz S, Biswas D, Jahan R. Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol Appl Biochem. 2016;63(1):145\u201350.","journal-title":"Biotechnol Appl Biochem"},{"key":"3763_CR97","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.neuropharm.2013.04.008","volume":"72","author":"J Kosaraju","year":"2013","unstructured":"Kosaraju J, Gali CC, Khatwal RB, Dubala A, Chinni S, Holsinger RMD, et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer\u2019s disease. Neuropharmacology. 2013;72:291\u2013300.","journal-title":"Neuropharmacology"},{"key":"3763_CR98","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","volume":"76","author":"PL McClean","year":"2014","unstructured":"McClean PL, H\u00f6lscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease. Neuropharmacology. 2014;76:57\u201367.","journal-title":"Neuropharmacology"},{"issue":"5","key":"3763_CR99","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s11357-011-9303-8","volume":"34","author":"S Chen","year":"2012","unstructured":"Chen S, Liu A, An F, Yao W, Gao X. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer\u2019s disease by exendin-4. Age (Omaha). 2012;34(5):1211\u201324.","journal-title":"Age (Omaha)"},{"key":"3763_CR100","doi-asserted-by":"crossref","unstructured":"Esterline R, Oscarsson J, Burns J. A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer\u2019s disease? In 2020. p. 113\u201340.","DOI":"10.1016\/bs.irn.2020.03.018"},{"issue":"5","key":"3763_CR101","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013;36(5):1384\u201395.","journal-title":"Diabetes Care"},{"key":"3763_CR102","unstructured":"Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;13:372:m4573."},{"issue":"1","key":"3763_CR103","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7812\/TPP\/22.137","volume":"27","author":"CA Blanco","year":"2023","unstructured":"Blanco CA, Garcia K, Singson A, Smith WR. Use of SGLT2 inhibitors reduces heart failure and hospitalization: a multicenter, real-world evidence study. Perm J. 2023;27(1):77\u201387.","journal-title":"Perm J"},{"issue":"4","key":"3763_CR104","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3233\/JAD-159002","volume":"45","author":"A Claxton","year":"2015","unstructured":"Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer\u2019s disease dementia. J Alzheimer\u2019s Dis. 2015;45(4):1269\u201370.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"3","key":"3763_CR105","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-2008-13309","volume":"13","author":"MA Reger","year":"2008","unstructured":"Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-\u03b2 in memory-impaired older adults. J Alzheimer\u2019s Dis. 2008;13(3):323\u201331.","journal-title":"J Alzheimer\u2019s Dis"},{"issue":"3","key":"3763_CR106","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","volume":"27","author":"MA Reger","year":"2006","unstructured":"Reger MA, Watson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27(3):451\u20138.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"3763_CR107","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","volume":"77","author":"S Craft","year":"2020","unstructured":"Craft S, Raman R, Chow TW, Rafii MS, Sun C-K, Rissman RA, et al. Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia. JAMA Neurol. 2020;77(9):1099.","journal-title":"JAMA Neurol"},{"issue":"1","key":"3763_CR108","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment. Arch Neurol. 2012;69(1):29.","journal-title":"Arch Neurol"},{"issue":"6","key":"3763_CR109","doi-asserted-by":"publisher","first-page":"e081401","DOI":"10.1136\/bmjopen-2023-081401","volume":"14","author":"I Koychev","year":"2024","unstructured":"Koychev I, Adler AI, Edison P, Tom B, Milton JE, Butchart J, et al. Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults. BMJ Open. 2024;14(6):e081401.","journal-title":"BMJ Open"},{"key":"3763_CR110","doi-asserted-by":"publisher","first-page":"111898","DOI":"10.1016\/j.mad.2023.111898","volume":"218","author":"T Davidy","year":"2024","unstructured":"Davidy T, Yore I, Cukierman-Yaffe T, Ravona-Springer R, Livny A, Lesman-Segev OH, et al. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design. Mech Ageing Dev. 2024;218:111898.","journal-title":"Mech Ageing Dev"},{"key":"3763_CR111","doi-asserted-by":"crossref","unstructured":"Sinclair SH, Miller E, Talekar KS, Schwartz SS. Diabetes mellitus associated neurovascular lesions in the retina and brain: a review. Front Ophthalmol. 2022;2:1012804.","DOI":"10.3389\/fopht.2022.1012804"},{"issue":"5","key":"3763_CR112","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ana.20474","volume":"57","author":"P Bubber","year":"2005","unstructured":"Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol. 2005;57(5):695\u2013703.","journal-title":"Ann Neurol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03763-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03763-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T14:08:46Z","timestamp":1734530926000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03763-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03763-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"582"}}